Magdalena Kuzma-Kozakiewicz
Clinical trials in pediatric ALS: a TRICALS feasibility study.
Kliest T, van Eijk R, Al-Chalabi A, Albanese A, Andersen P, Amador M, BrÅthen G, Brunaud-Danel V, Brylev L, Camu W, de Carvalho M, Cereda C, Cetin H, Chaverri D, Chio A, Corcia P, Couratier P, De Marchi F, Desnuelle C, van Es M, Esteban J, Filosto M, GarcÍa Redondo A, Grosskreutz J, Hanemann C, Holmøy T, HØyer H, Ingre C, Koritnik B, Kuzma-Kozakiewicz M, Lambert T, Leigh P, Lunetta C, Mandrioli J, McDermott C, Meyer T, Mora J, Petri S, Povedano M, Reviers E, Riva N, Roes K, Rubio M, Salachas F, Sarafov S, Sorarù G, Stević Z, Svenstrup K, MØller A, Turner M, Van Damme P, Van Leeuwen L, Varona L, VÁzquez Costa J, Weber M, Hardiman O, van den Berg L. Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotroph Lateral Scler Frontotemporal Degener 2022; 23:481-488.
16.02.2022Clinical trials in pediatric ALS: a TRICALS feasibility study.
16.02.2022Amyotroph Lateral Scler Frontotemporal Degener 2022; 23:481-488
Kliest Tessa, van Eijk Ruben P A, Al-Chalabi Ammar, Albanese Alberto, Andersen Peter M, Amador Maria Del Mar, BrÅthen Geir, Brunaud-Danel Veronique, Brylev Lev, Camu William, de Carvalho Mamede, Cereda Cristina, Cetin Hakan, Chaverri Delia, Chio Adriano, Corcia Philippe, Couratier Philippe, De Marchi Fabiola, Desnuelle Claude, van Es Michael A, Esteban JesÚs, Filosto Massimiliano, GarcÍa Redondo Alberto, Grosskreutz Julian, Hanemann Clemens O, Holmøy Trygve, HØyer Helle, Ingre Caroline, Koritnik Blaž, Kuzma-Kozakiewicz Magdalena, Lambert Thomas, Leigh Peter N, Lunetta Christian, Mandrioli Jessica, McDermott Christopher J, Meyer Thomas, Mora Jesus S, Petri Susanne, Povedano Monica, Reviers Evy, Riva Nilo, Roes Kit C B, Rubio Miguel Á, Salachas François, Sarafov Stayko, Sorarù Gianni, Stević Zorica, Svenstrup Kirsten, MØller Anette Torvin, Turner Martin R, Van Damme Philip, Van Leeuwen Lucie A G, Varona Luis, VÁzquez Costa Juan F, Weber Markus, Hardiman Orla, van den Berg Leonard H
ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis
Lingor P, Koch J, Ludolph A, Frontini R, Blankenstein C, Bidner H, Kuzma-Kozakiewicz M, Benatar M, Günther R, Neuwirth C, Leha A, Hilgers R, Friede T, Camu W, Weber M, ROCK-ALS Investigators. ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Front Neurol 2019; 10:293.
27.03.2019ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis
27.03.2019Front Neurol 2019; 10:293
Lingor Paul, Koch Jan C, Ludolph Albert, Frontini Roberto, Blankenstein Christiane, Bidner Helen, Kuzma-Kozakiewicz Magdalena, Benatar Michael, Günther René, Neuwirth Christoph, Leha Andreas, Hilgers Reinhard, Friede Tim, Camu William, Weber Markus, ROCK-ALS Investigators